Historically, CROs have grown by
building the scales for the services that pharma cos and biotechs wanted to
outsource due to a number of reasons, from reducing the overheads, to
cost-effective operations, to downsizing the headcount for effective
management, etc. As a result, operational efficiency, large scales and past
experiences have been the key value propositions, with relatively lesser focus
on differentiated offerings, of course with a few exceptions.
However, with BioPharma now riding on a wave of
innovative technologies, from AI-driven discovery to real-world evidence
platforms, from protein therapeutics to RNA modalities, from gene therapy to
cell therapy, from precision medicine to companion diagnostics, etc., the CROs
must adapt their strategy to address Biopharma’s evolving needs in the coming
As we usher in a new decade, this is a fine
moment for the CROs to anticipate biopharma’s requirements and adopt strategy
anchored around differentiated technologies, and start building for the
We have attempted to outline such a strategy
using 3 distinct:
- Artificial Intelligence in Drug Discovery
- Biologics Drug Development – High Concentration Protein Formulation
- Microphysiological Systems and 3D-Bioprinted Biological Systems
Strategic partnerships with early stage
biotechs with promising technologies will potentially create a mutually
benefiting relationship, wherein CROs will benefit from offering cutting edge
technologies to their clients whereas biotechs will benefit from a broader
client exposure within CRO’s network.
Our in-depth understanding of differentiated
technologies uniquely positions us to identify and evaluate prudent strategic partnership/investment
opportunities. We will be delighted to set up a skunk-work project with your team to identify potential
areas of interest (beyond the technologies mentioned above as well) and set the
foundation for your future strategy.
download our Next Generation CROs –
Differentiated Technologies Today That Will Pay-Off Tomorrow.